Form 4: Madrigal Pharmaceuticals Director James Daly Executes Stock Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Director James Daly exercised stock options and sold shares of Madrigal Pharmaceuticals common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On April 1st and 2nd, 2024, James Daly, a director of Madrigal Pharmaceuticals, engaged in multiple transactions involving the company's common stock.
- Daly exercised stock options to acquire 20,000 shares at $100.45 and 1,577 shares at $105.08 on April 1st, and 10,912 shares at $105.08 on April 2nd.
- Concurrently, Daly sold a total of 24,344 shares on April 1st and 11,012 shares on April 2nd at prices ranging from $242.58 to $267.21 per share.
- These sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 16, 2023.
- Following these transactions, Daly directly owns 1,198 shares of Madrigal Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading plan and do not necessarily reflect a change in the director's outlook on the company.
Industry Context
Form 4 filings are standard disclosures for corporate insiders and provide transparency into their trading activities. The use of a 10b5-1 plan indicates pre-planned sales to avoid accusations of insider trading.
Comparison to Industry Standards
- Form 4 filings are a standard regulatory requirement for corporate insiders in publicly traded companies, ensuring transparency in their trading activities.
- The use of Rule 10b5-1 trading plans is a common practice among executives to schedule stock sales in advance, mitigating concerns about insider trading, similar to practices seen at companies like Pfizer or Amgen.
- The reported transactions are consistent with typical insider trading activities observed across the pharmaceutical industry, where executives often exercise stock options and sell shares for personal financial management.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
- The use of a 10b5-1 plan provides transparency and reduces concerns about insider trading, which can positively impact shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 2023-11-16 | Date of adoption of Rule 10b5-1 trading plan |
| 2024-04-01 | Date of stock option exercises and share sales |
| 2024-04-02 | Date of stock option exercises and share sales |
| 2024-04-03 | Date of signature for Power of Attorney |
| 2024-06-17 | Expiration date of some stock options |
| 2024-06-27 | Expiration date of some stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.